logo-loader
viewSareum Holdings PLC

Sareum shares rocket after ProNAi Therapeutics licenses cancer drug

Shares in Sareum have rocketed over 150% after it announced its cancer drug candidate has been licensed to ProNAi Therapeutics.

Cancer cell graphic
“This is a major achievement for our lead candidate as well as for Sareum."

Shares in Sareum Holdings PLC (LON:SAR) rocketed over 150% after it announced its cancer drug candidate has been licensed to ProNAi Therapeutics, Inc (NASDAQ:DNAI).

Under Sareum’s agreements with Cancer Research Technology (CRT) and the CRT Pioneer Fund, the drug discovery group will receive US$1.9mln as an up-front payment and potential future milestone payments of up to US$88.4mln, some of which will be paid within the next year.

Sareum’s Chk1 Inhibitor CCT245737 (to be renamed PNT737) was originally developed in a research collaboration between the London Institute of Cancer Research, Sareum and CRT.

The ChK1 or checkpoint kinase 1 inhibitor is shown to prevent cancer cells from multiplying by attacking its faulty DNA, meaning the cancer self-destructs.

The group sees potential for synergy between standard cancer therapies - such as radio- or chemotherapy - and checkpoint inhibitors as a combination therapy.

“This is a major achievement for our lead candidate as well as for Sareum. Starting with the initial discovery, we have contributed financially and scientifically to the on-going development of the programme into clinical trials. The returns from this research investment will be realised in this licence agreement, validating our strategy and business model,” said chief executive Tim Mitchell.

“ProNAi is in a strong position to further the development of PNT737 and plans to expand its development into the United States and with broader clinical studies. We look forward to reporting on their progress,” he added.

"ProNAi has a world-class oncology development team and is well-capitalised, and we believe these studies and the ongoing development strategy for this drug are in excellent hands,” said Robert James of Sixth Element Capital LLP, managers of the CRT Pioneer Fund.

Shares shot up 150% to a three-year high of 1.56p. 

Quick facts: Sareum Holdings PLC

Price: 0.325 GBX

AIM:SAR
Market: AIM
Market Cap: £9.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Sareum Holdings says Phase I clinical trials for CHK1 could potentially...

Tim Mitchell, chief executive officer at cancer drug discovery company Sareum Holdings (LON:SAR), talks to Proactive Investors about the progress achieved by all of its programmes in the half year ended December 31, 2015. He says Phase I clinical trials for CHK1, its most advanced...

on 02/24/2016

2 min read